MCL Literature Feed
846 papers on mantle cell lymphoma from PubMed. Updated daily.
This case report details a rare presentation of MCL transformed to DLBCL with urinary symptoms from prostate involvement, highlighting lymphoma as a differential diagnosis requiring aggressive chemoimmunotherapy and transplant.
This paper describes the high frequency and characteristic patterns of gastrointestinal involvement in MCL, often as lymphomatous polyposis, highlighting the importance of endoscopy for accurate staging.
This review highlights ongoing trials moving CAR-T and bispecific antibodies into earlier lines of MCL therapy, signaling a potential paradigm shift away from traditional chemoimmunotherapy.
This case series reports uveal melanoma development in patients on BTK inhibitors, suggesting a potential rare but serious toxicity and warranting increased ophthalmologic surveillance for this common MCL therapy.
The recent FDA approval of Lisocabtagene Maraleucel provides a new CAR-T therapy for relapsed/refractory MCL, offering high response rates but requiring careful management of severe toxicities.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
Hemoadsorption with CytoSorb safely reversed severe, refractory cytokine release syndrome in post-CAR-T patients, including one with MCL, offering a potential supportive strategy for managing life-threatening toxicities.
This review summarizes current MCL risk stratification (MIPI, TP53), highlights emerging genomic biomarkers, and emphasizes MRD monitoring as a key dynamic tool for personalizing therapy, especially for high-risk patients.
This review advocates for adding a BTKi to frontline immunochemotherapy for transplant-eligible patients as a new standard of care, while also summarizing its emerging role in older patients.
This case report describes the rare anaplastic pleomorphic variant of MCL, highlighting its aggressive features and the critical role of pathology in diagnosing high-risk disease subtypes.
This paper likely characterizes the clinical features, treatment patterns, and poor outcomes of isolated central nervous system relapse in MCL, highlighting a major unmet clinical need.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This case report of synchronous gastric adenocarcinoma and mantle cell lymphoma highlights the need for thorough pathological evaluation of surgical specimens, as MCL can be an incidental finding.
A phase 1 study in Chinese relapsed/refractory B-cell NHL patients establishes the recommended dose of the HDAC inhibitor abexinostat (80 mg BID) with promising activity, supporting further development.
This preclinical study identifies CEACAM1 as a novel activator of B-cell receptor signaling by recruiting SYK, revealing a new potential therapeutic target and mechanism of resistance to BCR inhibitors.
This myeloma review outlines strategies to overcome proteasome inhibitor resistance by targeting other proteostasis pathways, providing a rationale for exploring similar combinations in relapsed/refractory MCL.
The novel circular RNA-based biomarker, circSCORE, demonstrates prognostic value in relapsed/refractory MCL, offering a new tool for risk stratification in this high-risk patient population.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A novel single-cell method integrating biophysical properties with transcriptomics identifies distinct MCL subpopulations, suggesting cell mechanics could be a new biomarker for tumor heterogeneity and therapeutic resistance.
In a modern Canadian cohort, allogeneic transplant for relapsed/refractory MCL achieved a 5-year overall survival of 68.1%, confirming its ongoing relevance as a curative-intent therapy.
This preclinical study of a selective immunoproteasome inhibitor in ALL suggests a potential future strategy for MCL to achieve efficacy similar to bortezomib with potentially less off-target toxicity.
This retrospective series of six patients establishes that esophageal multiple lymphomatous polyposis in MCL signifies high tumor burden and a very poor prognosis, with median survival under two years.
This study compares bendamustine-rituximab (BR) versus R-CHOP as initial therapy for transplant-ineligible MCL patients, providing evidence to guide frontline treatment selection in this common clinical setting.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A rare B-ALL subtype with a MEF2D::BCL9 fusion can mimic blastoid MCL by co-expressing CD5 and SOX11, highlighting a critical diagnostic pitfall requiring molecular confirmation.
Overexpression of IL-16 drives BTKi resistance via the CD9/NF-κB/AKT axis in MCL models, presenting a novel therapeutic target to overcome treatment failure and restore drug sensitivity.
In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.
In frontline MCL, pre-treatment ctDNA levels and TP53 mutations predict poor survival, while post-treatment ctDNA clearance identifies patients with favorable outcomes, establishing its clinical utility for prognosis.
This review provides a practical guide for differentiating aggressive B-cell lymphomas, including mantle cell lymphoma, emphasizing the integration of morphology, immunohistochemistry, and molecular testing for accurate diagnosis and classification.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This review summarizes favorable outcomes for CAR-T and bispecific antibodies in relapsed/refractory MCL, detailing their integration into the treatment paradigm for patients with poor prognoses post-BTKi.
High p62 expression predicts poor survival in MCL by upregulating CCND1 transcription via Nrf2, identifying p62 as a novel prognostic biomarker and potential non-BTK/BCL2 therapeutic target.
This phase 2 trial shows ibrutinib is effective in high-risk, previously untreated smoldering MCL, suggesting early intervention with a BTKi can delay progression in this traditionally observed population.
A novel single-cell genomic research model tracks MCL clonal evolution, providing a high-resolution tool to dissect mechanisms of therapeutic resistance and identify potential new targets.
This review synthesizes mechanisms of BTKi resistance and highlights next-generation strategies like noncovalent BTKi and PROTACs to overcome this critical challenge in relapsed/refractory MCL.